EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats

Birgit Vogler, Annette Kuhn, Kimberly D Mackenzie, Jennifer Stratton, Mária Dux iD, Karl Messlinger iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241713471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Birgit Vogler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Physiology and Pathophysiology, Friedrich-Alexander-University, D-91054 Erlangen, Germany. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Receptors, Calcitonin Gene-Related Peptide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexander von Humboldt Foundation, Teva Pharmaceuticals, the Alexander von Humboldt Foundation (Research Group Linkage Program between the Institutes of Physiology of the FAU Erlangen-Nürnberg and the University of S….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment with the anti-CGRP antibody fremanezumab is successful in the prevention of chronic and frequent episodic migraine. In preclinical rat experiments, fremanezumab has been shown to reduce calcitonin gene-related peptide (CGRP) release from trigeminal tissues and aversive behaviour to noxious facial stimuli, which are characteristic pathophysiological changes accompanying severe primary headaches. To further decipher the effects of fremanezumab that underlie these antinociceptive effects in rats, immunohistochemistry and ELISA techniques were used to analyse the content and concentration of CGRP in the trigeminal ganglion, as well as the ratio of trigeminal ganglion neurons which are immunoreactive to CGRP and CGRP receptor components, 1–10 days after subcutaneous injection of fremanezumab (30 mg/kg) compared to an isotype control antibody. After fremanezumab treatment, the fraction of trigeminal ganglion neurons which were immunoreactive to CGRP and the CGRP receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) was significantly lowered compared to the control. The content and concentration of CGRP in trigeminal ganglia were not significantly changed. A long-lasting reduction in CGRP receptors expressed in trigeminal afferents may contribute to the attenuation of CGRP signalling and antinociceptive effects of monoclonal anti-CGRP antibodies in rats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related PeptideReceptors, Calcitonin Gene-Related PeptideAnimalsRatsAntibodies, MonoclonalNeuronsAnalgesics

Stichwörter der Autor:innen

CGRP releasecalcitonin gene-related peptidefremanezumabmigraine painmonoclonal antibodyrattrigeminal ganglion

Substanzen

Calcitonin Gene-Related PeptidefremanezumabReceptors, Calcitonin Gene-Related PeptideAntibodies, MonoclonalAnalgesics

Autor:innen und Institutionen

  • Institute of Physiology and Pathophysiology, Friedrich-Alexander-University, D-91054 Erlangen, Germany.
  • Teva Pharmaceuticals, Redwood City, CA 94063, USA.
  • Department of Physiology, University of Szeged, H-6720 Szeged, Hungary.

ORCID-Profile: Mária Dux, Karl Messlinger

Förderung

  • Alexander von Humboldt Foundation
  • Teva Pharmaceuticals
  • the Alexander von Humboldt Foundation (Research Group Linkage Program between the Institutes of Physiology of the FAU Erlangen-Nürnberg and the University of S…
  • the Friedrich-Alexander-Universität Erlangen-Nürnberg within the funding program “Open Access Publication Funding”

Zitieren

APA

Vogler, B., Kuhn, A., Mackenzie, K. D., Stratton, J., Dux, M., & Messlinger, K. (2023). The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241713471

Vancouver

Vogler B, Kuhn A, Mackenzie KD, Stratton J, Dux M, Messlinger K. The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241713471

BibTeX
@article{Vogler2023,
  author = {Vogler, Birgit and Kuhn, Annette and Mackenzie, Kimberly D and Stratton, Jennifer and Dux, Mária and Messlinger, Karl},
  title = {The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241713471}
}
Kostenlos starten →